Concentrations of IL-27, ADA and IFN-γ in pleural fluid and/or serum according to study cohort*
| Variable | Beijing cohort | Wuhan cohort | ||||||
| TPE (n=51) | MPE (n=61) | PPE (n=28) | Miscellaneous (n=14) | TPE (n=44) | MPE (n=47) | PPE (n=19) | Miscellaneous (n=10) | |
| IL-27 | ||||||||
| PF, ng/L | 892.7±35.2†‡ | 298.3±13.1 | 270.4±16.1 | 252.3±12.1 | 885.3±39.2† | 288.7±13.0 | 306.8±22.6 | 252.3±18.3 |
| Serum, ng/L | 334.5±25.7 | 326.6±9.2 | 321.2±21.2 | 309.9±11.9 | 314.7±10.0 | 320.7±10.2 | 312.6±18.7 | 279.4±19.1 |
| ADA | ||||||||
| PF, U/L | 49.2±3.7†‡ | 15.7±1.3 | 14.5±1.6 | 15.9±2.0 | 48.2±4.9† | 13.3±1.2 | 14.7±1.1 | 18.6±2.0 |
| Serum, U/L | 13.8±0.8 | 13.5±0.9 | 14.2±1.5 | 15.0±0.9 | 12.5±0.9 | 13.9±1.2 | ||
| IFN-γ | ||||||||
| PF, ng/L | 1,169.8§¶ (341.9‒3881.6) | 29.2 (20.2‒39.9) | 32.6 (18.5‒47.3) | 38.2 (26.5‒57.4) | 1,126.3§ (322.6‒3177.0) | 24.9 (18.3‒38.1) | 44.2 (19.9‒106.0) | 47.7 (32.4‒106.6) |
| Serum, ng/L | 27.1§ (14.7‒51.3) | 12.4 (8.7‒15.6) | 16.8 (9.7‒26.0) | 11.8 (8.8‒27.2) | 30.7§ (12.7‒50.5) | 11.8 (8.3‒13.2) | 10.7 (8.3‒15.6) | 11.2 (10.2‒13.8) |
*Data are presented as mean ±SEM or median (25th ‒ 75th centile). †p<0.001 compared with each non-TPE group using analysis of variance (ANOVA) followed by Bonferroni’s test; ‡p<0.001 compared with the corresponding serum using paired t test; §p<0.001 with each non-TPE group using Kruskal-Wallis ANOVA; ¶p<0.001 compared with the corresponding serum using Wilcoxon signed-rank test; **p<0.05 compared with TPE group using ANOVA followed by Bonferroni’s test.
ADA, adenosine deaminase; IFN, interferon; IL, interleukin; MPE, malignant pleural effusion; PF, pleural fluid; PPE, parapneumonic pleural effusion; TPE, tuberculous pleural effusion.